Affiliation: University of Sydney
- Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) studyWendy Hague
NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia
Am Heart J 145:643-51. 2003..The aim of this subgroup analysis was to assess the effects of pravastatin in women...
- Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trialAnthony Keech
National Health Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, Australia
Diabetes Care 26:2713-21. 2003..0 years, on the risk of CHD death or nonfatal myocardial infarction and other cardiovascular outcomes in 1,077 LIPID patients with diabetes and 940 patients with impaired fasting glucose (IFG)...
- Relationship between lipid levels and clinical outcomes in the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels?R John Simes
National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Australia
Circulation 105:1162-9. 2002..0 to 7.0 mmol/L at baseline. Secondary objectives included assessment of CHD event reduction according to lipid levels...
- Low-dose aspirin for preventing recurrent venous thromboembolismTimothy A Brighton
Department of Haematology, South Eastern Area Laboratory Services SEALS, Prince of Wales Hospital, Sydney, Australia
N Engl J Med 367:1979-87. 2012..Patients who have had a first episode of unprovoked venous thromboembolism have a high risk of recurrence after anticoagulants are discontinued. Aspirin may be effective in preventing a recurrence of venous thromboembolism...